Actively Recruiting
A Pilot Study of 68Ga-FAPI-RGD PET/CT Imaging in Lung Cancer Patients
Led by Peking Union Medical College Hospital · Updated on 2024-07-05
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new dual-target imaging agent called 68Ga-FAPI-RGD for PET/CT scans in patients with lung cancer. This agent targets both fibroblast activating protein (FAP) on tumor tissues and integrin b1vb23 receptors on blood vessels, aiming to improve visualization of lung cancer lesions. The study compares this novel agent with conventional 18F-FDG and single-target agents 68Ga-FAPI and 68Ga-RGD to overcome limitations of current imaging methods. Participants will receive intravenous injections of the imaging agents, including 68Ga-FAPI-RGD, 18F-FDG, 68Ga-FAPI, and 68Ga-RGD, at doses based on body weight. Each patient undergoes PET/CT scans within two weeks after receiving 68Ga-FAPI-RGD and one of the other agents. Three experimental groups compare 68Ga-FAPI-RGD with either 18F-FDG, 68Ga-FAPI, or 68Ga-RGD to assess diagnostic performance. During the study, participants will have PET/CT scans and monitoring for diagnostic accuracy over about one year. Researchers will evaluate the imaging agents' uptake at different times and radiation dosimetry. The trial includes assessments of lung cancer lesions using these agents to understand their ability to detect tumors effectively. Participants' safety and study compliance are monitored throughout the trial period.
CONDITIONS
Brief Title
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed or suspected lung cancer
- Undergo 68Ga-FAPI-RGD and 18F-FDG (or 68Ga-FAPI or 68Ga-RGD) PET/CT scans within 2 weeks
- Signed written consent
You will not qualify if you...
- Pregnancy
- Breastfeeding
- Any medical condition that may significantly interfere with study compliance according to the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 2 weeks
Participants undergo PET/CT scans using 68Ga-FAPI-RGD combined with either 18F-FDG, 68Ga-FAPI, or 68Ga-RGD to assist in lung cancer diagnosis.
2 to 3 visits depending on imaging agents used
Duration - Up to 1 year
Participants are monitored for diagnostic performance and dosimetry outcomes for up to 1 year following imaging.
Follow-up assessments as scheduled by the study team
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
Research Team
Z
Zhaohui Zhu, MD,PHD
R
Rongxi Wang
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here